BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36463731)

  • 21. Identifying primary site of lung-limited Cancer of unknown primary based on relative gene expression orderings.
    Li M; Li H; Hong G; Tang Z; Liu G; Lin X; Lin M; Qi L; Guo Z
    BMC Cancer; 2019 Jan; 19(1):67. PubMed ID: 30642283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary.
    Laprovitera N; Riefolo M; Porcellini E; Durante G; Garajova I; Vasuri F; Aigelsreiter A; Dandachi N; Benvenuto G; Agostinis F; Sabbioni S; Berindan Neagoe I; Romualdi C; Ardizzoni A; Trerè D; Pichler M; D'Errico A; Ferracin M
    Mol Oncol; 2021 Oct; 15(10):2732-2751. PubMed ID: 34075699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progress in refining the clinical management of cancer of unknown primary in the molecular era.
    Rassy E; Pavlidis N
    Nat Rev Clin Oncol; 2020 Sep; 17(9):541-554. PubMed ID: 32350398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting the site of origin of tumors by a gene expression signature derived from normal tissues.
    Staub E; Buhr HJ; Gröne J
    Oncogene; 2010 Aug; 29(31):4485-92. PubMed ID: 20514016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels.
    Ramarao-Milne P; Kondrashova O; Patch AM; Nones K; Koufariotis LT; Newell F; Addala V; Lakis V; Holmes O; Leonard C; Wood S; Xu Q; Mukhopadhyay P; Naeini MM; Steinfort D; Williamson JP; Bint M; Pahoff C; Nguyen PT; Twaddell S; Arnold D; Grainge C; Basirzadeh F; Fielding D; Dalley AJ; Chittoory H; Simpson PT; Aoude LG; Bonazzi VF; Patel K; Barbour AP; Fennell DA; Robinson BW; Creaney J; Hollway G; Pearson JV; Waddell N
    ESMO Open; 2022 Aug; 7(4):100540. PubMed ID: 35849877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
    Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
    Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis and management of metastatic neoplasms with unknown primary.
    Bochtler T; Löffler H; Krämer A
    Semin Diagn Pathol; 2018 May; 35(3):199-206. PubMed ID: 29203116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer of Unknown Primary in the Molecular Era.
    Kato S; Alsafar A; Walavalkar V; Hainsworth J; Kurzrock R
    Trends Cancer; 2021 May; 7(5):465-477. PubMed ID: 33516660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience.
    Pauli C; Bochtler T; Mileshkin L; Baciarello G; Losa F; Ross JS; Pentheroudakis G; Zarkavelis G; Yalcin S; Özgüroğlu M; Beringer A; Scarato J; Mueller-Ohldach M; Thomas M; Moch H; Krämer A
    Oncologist; 2021 May; 26(5):e769-e779. PubMed ID: 33687747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer.
    Simons MJHG; Retèl VP; Ramaekers BLT; Butter R; Mankor JM; Paats MS; Aerts JGJV; Mfumbilwa ZA; Roepman P; Coupé VMH; Uyl-de Groot CA; van Harten WH; Joore MA
    Pharmacoeconomics; 2021 Dec; 39(12):1429-1442. PubMed ID: 34405371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
    Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
    JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling.
    Varadhachary G
    Clin Cancer Res; 2013 Aug; 19(15):4027-33. PubMed ID: 23519898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review.
    Pentheroudakis G; Greco FA; Pavlidis N
    Cancer Treat Rev; 2009 May; 35(3):221-7. PubMed ID: 19046817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Radiological diagnostics in CUP syndrome].
    Kazmierczak PM; Nikolaou K; Rominger A; Graser A; Reiser MF; Cyran CC
    Radiologe; 2014 Feb; 54(2):117-23. PubMed ID: 24500247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accurate classification of metastatic brain tumors using a novel microRNA-based test.
    Mueller WC; Spector Y; Edmonston TB; St Cyr B; Jaeger D; Lass U; Aharonov R; Rosenwald S; Chajut A
    Oncologist; 2011; 16(2):165-74. PubMed ID: 21273512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extensive diagnostic work-up for patients with carcinoma of unknown primary.
    Meijer L; Verhoeven RHA; de Hingh IHJT; van de Wouw AJ; van Laarhoven HWM; Lemmens VEPP; Loef C
    Clin Exp Metastasis; 2021 Apr; 38(2):231-238. PubMed ID: 33515369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?
    Rassy E; Parent P; Lefort F; Boussios S; Baciarello G; Pavlidis N
    Crit Rev Oncol Hematol; 2020 Mar; 147():102882. PubMed ID: 32106012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and validation of a gene expression tumour classifier for cancer of unknown primary.
    Tothill RW; Shi F; Paiman L; Bedo J; Kowalczyk A; Mileshkin L; Buela E; Klupacs R; Bowtell D; Byron K
    Pathology; 2015 Jan; 47(1):7-12. PubMed ID: 25485653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP).
    Es HA; Mahdizadeh H; Asl AAH; Totonchi M
    Sci Rep; 2021 Jul; 11(1):15112. PubMed ID: 34302033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical Practice of Carcinoma of Unknown Primary].
    Hasegawa Y; Mukai H
    Gan To Kagaku Ryoho; 2018 Jun; 45(6):891-893. PubMed ID: 30026408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.